BRIEF-Amgen Canada - announces new study results of Repatha in statin-intolerant patients

Mon Apr 4, 2016 6:22am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 4 (Reuters) - Amgen Canada

* New detailed data from phase 3 gauss-3 trial evaluating repatha in patients with high cholesterol who cannot tolerate statins

* Repatha shown to significantly reduce LDLC-C by about 55 percent after 24 weeks compared to ezetimibe Source text for Eikon: Further company coverage: